Darunavir Inhibitory Quotient Predicts the 48-Week Virological Response to Darunavir-Based Salvage Therapy in Human Immunodeficiency Virus-Infected Protease Inhibitor-Experienced Patients

被引:22
|
作者
Molto, Jose [1 ]
Santos, Jose R. [1 ]
Perez-Alvarez, Nuria [1 ,3 ]
Cedeno, Samandhy [2 ]
Miranda, Cristina [1 ]
Khoo, Saye [5 ]
Else, Laura [5 ]
Llibre, Josep Maria [1 ]
Valle, Marta [4 ]
Clotet, Bonaventura [1 ,2 ]
机构
[1] Hosp Univ Germans Trias & Pujol, Lluita SIDA Fdn, Badalona, Spain
[2] Hosp Univ Germans Trias & Pujol, IrsiCaixa Fdn, Badalona, Spain
[3] Univ Politecn Barcelona, Barcelona, Spain
[4] Hosp Santa Creu & Sant Pau, Inst Recerca, Ctr Invest Medicament, Barcelona, Spain
[5] Univ Liverpool, Dept Pharmacol, Liverpool L69 3BX, Merseyside, England
关键词
D O I
10.1128/AAC.00520-08
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The aim of this study was to evaluate the relationship between the virological response to darunavir-based salvage antiretroviral therapy and the darunavir genotypic and virtual inhibitory quotients (gIQ and vIQ, respectively). Thirty-seven HIV-infected patients failing protease inhibitor-based antiretroviral regimens who started salvage therapy containing darunavir-ritonavir were prospectively studied. The primary outcome of the study was a viral load (VL) of < 50 copies/ml at week 48. The trough concentrations of darunavir in plasma, the number of darunavir resistance mutations, the change in the 50% inhibitory concentration (IC50) of darunavir in the virtual phenotype, and the darunavir gIQ and vIQ were correlated with the virological outcome in regression analyses adjusted by the number of active drugs in the background regimen. The VL was < 50 copies/ml in 56.8% of patients at week 48. Changes in the VL were not significantly associated with the darunavir concentration (P = 0.304), the number of darunavir resistance mutations (P = 0.695), or the change in the IC50 (P = 0.750). However, patients with darunavir vIQs of >= 1.5 had a 12-fold greater chance of achieving a >= 1 log(10) reduction in the VL (odds ratio [OR], 12.7; 95% confidence interval [95% CI], 1.9 to 81.6; P = 0.007), and a 5-fold greater chance of achieving a VL of < 50 copies/ml (OR, 5.4; 95% CI, 1.2 to 24.5; P = 0.028), at week 48 than patients with darunavir vIQs of < 1.5. The positive and negative predictive values of this darunavir vIQ cutoff for achieving a VL of < 50 copies/ml at week 48 were 70% and 69%, respectively. The darunavir vIQ predicts virological response to darunavir-based salvage therapy better than the darunavir trough concentration or resistance mutations alone. We suggest targeting a darunavir vIQ of 1.5 for achieving long-term viral suppression.
引用
收藏
页码:3928 / 3932
页数:5
相关论文
共 34 条
  • [1] Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients
    Descamps, Diane
    Lambert-Niclot, Sidonie
    Marcelin, Anne-Genevieve
    Peytavin, Gilles
    Roquebert, Benedicte
    Katlama, Christine
    Yeni, Patrick
    Felices, Mathieu
    Calvez, Vincent
    Brun-Vezinet, Francoise
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (03) : 585 - 592
  • [2] Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients
    Marcelin, AGV
    Lamotte, C
    Delaugerre, C
    Ktorza, N
    Mohand, HA
    Cacace, R
    Bonmarchand, M
    Wirden, M
    Simon, A
    Bossi, P
    Bricaire, F
    Costagliola, D
    Katlama, C
    Peytavin, G
    Calvez, V
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (02) : 594 - 600
  • [3] Impact of baseline protease mutations on virological response to darunavir-ritonavir-containing therapy in protease inhibitor-experienced patients (PREDIZISTA Study)
    Pellegrin, I.
    Wittkop, L.
    Breilh, D.
    Merel, P.
    Winters, B.
    Bonarck, M.
    Neau, D.
    Bollens, D.
    Pellegrin, J. L.
    Girard, P. M.
    Fleury, H. J. A.
    Saux, M. C.
    Thiebaut, R.
    Morand-Joubert, L.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S22 - S22
  • [4] Impact of baseline protease mutations on virological response to darunavir-ritonavir-containing therapy in protease inhibitor-experienced patients (PREDIZISTA Study)
    Pellegrin, I.
    Wittkop, L.
    Breilh, D.
    Merel, P.
    Winters, B.
    Bonarek, M.
    Neau, D.
    Bollens, D.
    Pellegrin, J. L.
    Girard, P. M.
    Fleury, H. J. A.
    Saux, M. C.
    Thiebaut, R.
    Morand-Joubert, L.
    ANTIVIRAL THERAPY, 2007, 12 : S22 - S22
  • [5] Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens
    de Requena, Daniel Gonzalez
    Bonora, Stefano
    Vigano, Ottavia
    Calcagno, Andrea
    Cometto, Cristina
    D'Avolio, Antonio
    Baietto, Lorena
    Ghisetti, Valeria
    Magnani, Silvia
    Ferramosca, Stefania
    Vitiello, Paola
    Galli, Massimo
    Rusconi, Stefano
    Di Perri, Giovanni
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (01) : 192 - 200
  • [6] Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients
    José Antonio Mata-Marín
    Gloria Huerta-García
    Juan Carlos Domínguez-Hermosillo
    Marcelino Chavez-García
    Marco Isaac Banda-Lara
    Nohemí Nuñez-Rodríguez
    Javier Enrique Cruz-Herrera
    Jorge Luis Sandoval-Ramírez
    Ivan Martínez-Abarca
    Alfredo Francisco Villagómez-Ruíz
    Bulmaro Manjarrez-Tellez
    Jesús Gaytán-Martínez
    AIDS Research and Therapy, 12
  • [7] Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients
    Antonio Mata-Marin, Jose
    Huerta-Garcia, Gloria
    Carlos Dominguez-Hermosillo, Juan
    Chavez-Garcia, Marcelino
    Isaac Banda-Lara, Marco
    Nunez-Rodriguez, Nohemi
    Enrique Cruz-Herrera, Javier
    Luis Sandoval-Ramirez, Jorge
    Martinez-Abarca, Ivan
    Francisco Villagomez-Ruiz, Alfredo
    Manjarrez-Tellez, Bulmaro
    Gaytan-Martinez, Jesus
    AIDS RESEARCH AND THERAPY, 2015, 12
  • [8] Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir
    Duval, X
    Lamotte, C
    Race, E
    Descamps, D
    Damond, F
    Clavel, F
    Leport, C
    Peytavin, G
    Vilde, JL
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) : 570 - 574
  • [9] Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients
    Le Moing, V
    Chêne, G
    Leport, C
    Lewden, C
    Duran, S
    Garré, M
    Masquelier, B
    Dupon, M
    Raffi, F
    CLINICAL INFECTIOUS DISEASES, 2002, 34 (02) : 239 - 247
  • [10] Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia
    Shulman, N
    Zolopa, A
    Havlir, D
    Hsu, A
    Renz, C
    Boller, S
    Jiang, P
    Rode, R
    Gallant, J
    Race, E
    Kempf, DJ
    Sun, E
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (12) : 3907 - 3916